CNTO6785
a fully human antiinterleukin 17 monoclonal antibody
Networked: 1
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Hsia, Elizabeth:
1 article
(01/2018)
|
| 2. | Jaller, Juan Jose:
1 article
(01/2018)
|
| 3. | Jeka, Slawomir:
1 article
(01/2018)
|
| 4. | Jia, Bin:
1 article
(01/2018)
|
| 5. | Kitumnuaypong, Tasanee:
1 article
(01/2018)
|
| 6. | Louthrenoo, Worawit:
1 article
(01/2018)
|
| 7. | Mann, Herman:
1 article
(01/2018)
|
| 8. | Matsievskaia, Galina:
1 article
(01/2018)
|
| 9. | Mease, Philip J:
1 article
(01/2018)
|
| 10. | Nie, Jing:
1 article
(01/2018)
|
Related Diseases
| 1. | Rheumatoid Arthritis
01/01/2018
- " CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study." 01/01/2018
- " To evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CNTO6785, a fully human monoclonal antibody that binds to human interleukin 17A, in patients with active rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX) therapy. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures